Clinical Trials Browser

Phase 1 × brigimadlin × 90 days × Clear all

NCT03964233 2026-02-18

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

Phase 1 Completed

Neoplasms

NCT05372367 2026-02-03

A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor

Phase 1 Completed

Other solid neoplasm

Solid Tumors